Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hickman

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Immunity & Ageing : I & A|April 18, 2017
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adultsLouis Fries, Vivek Shinde, Jeffrey J Stoddard, et al.
The Journal of Infectious Diseases|August 12, 2015
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing AgeGregory M Glenn, Louis F Fries, D Nigel Thomas, et al.
Vaccine|June 6, 2017
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing ageAllison August, Gregory M Glenn, Eloi Kpamegan, et al.
The Journal of Infectious Diseases|August 13, 2019
Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their InfantsFlor M Muňoz, Geeta K Swamy, Somia P Hickman, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineGregory M Glenn, Gale Smith, Louis Fries, et al.
Nature Medicine|August 22, 2006
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasisCarolyn G King, Takashi Kobayashi, Pedro J Cejas, et al.
Vaccine|August 6, 2011
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in MexicoConstantino López-Macías, Eduardo Ferat-Osorio, Alejandra Tenorio-Calvo, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Immunity & Ageing : I & A|April 18, 2017
Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adultsLouis Fries, Vivek Shinde, Jeffrey J Stoddard, et al.
The Journal of Infectious Diseases|August 12, 2015
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing AgeGregory M Glenn, Louis F Fries, D Nigel Thomas, et al.
Vaccine|June 6, 2017
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing ageAllison August, Gregory M Glenn, Eloi Kpamegan, et al.
The Journal of Infectious Diseases|August 13, 2019
Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their InfantsFlor M Muňoz, Geeta K Swamy, Somia P Hickman, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineGregory M Glenn, Gale Smith, Louis Fries, et al.
Nature Medicine|August 22, 2006
TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasisCarolyn G King, Takashi Kobayashi, Pedro J Cejas, et al.
Vaccine|August 6, 2011
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in MexicoConstantino López-Macías, Eduardo Ferat-Osorio, Alejandra Tenorio-Calvo, et al.
The Lancet. Respiratory Medicine|April 17, 2021
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trialTracy J Ruckwardt, Kaitlyn M Morabito, Emily Phung, et al.
Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Pageof 8